Holen Sie sich die Stockscreener-App
36.50
4.41%
1.54
Handel nachbörslich:
36.53
0.03
+0.08%
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - AOL.com
Aug Analyst Calls: Is Cogent Biosciences Inc forming a double bottomPortfolio Return Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Assessing Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Rising Institutional Interest - Sahm
A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions - Yahoo Finance
Trading the Move, Not the Narrative: (COGT) Edition - Stock Traders Daily
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding - AOL.com
RTW Investments Increases Cogent Biosciences Stake to 2.7% of PortfolioNews and Statistics - IndexBox
Kynam Capital Sells $48M in Cogent Biosciences Shares | Q4 2025 Portfolio UpdateNews and Statistics - IndexBox
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - The Motley Fool
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - AOL.com
Biotech share surges 372% before being sold as latest selection climbs 40% in 2026 - Bitget
FDA accepts Cogent’s drug filing for treatment of rare blood disorder - MSN
Cogent Biosciences stock climbs after FDA accepts key drug application - MSN
HC Wainwright Analysts Lift Earnings Estimates for COGT - MarketBeat
Is Cogent Biosciences (COGT) one of the best multibagger stocks to buy according to billionaires? - MSN
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Ascendis Pharma (ASND) - The Globe and Mail
COGT Forecast, Price Target & Analyst Ratings | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
What Cogent Biosciences (COGT)'s FDA Acceptance of Bezuclastinib NDA Means For Shareholders - Yahoo Finance
COGT Shares Climb After FDA Accepts Bezuclastinib NDA for Non-Advanced SM - Bitget
Technical Analysis: What is the long term forecast for Cogent Biosciences Inc stockMarket Sentiment Report & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
COGT: Wedbush Reiterates Outperform Rating with $55 Price Target - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Earns Outperform Rating from Wedbush - MarketBeat
Cinctive Capital Management LP Buys Shares of 111,058 Cogent Biosciences, Inc. $COGT - MarketBeat
Boothbay Fund Management LLC Cuts Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Valuation In Focus After FDA Accepts Bezuclastinib NDA For Systemic Mastocytosis - simplywall.st
Raymond James Maintains Strong Buy for Cogent Biosciences (COGT) March 2026 - Meyka
Jefferies Initiates Buy Rating for Cogent Biosciences (COGT) wit - GuruFocus
Cogent Biosciences assumed with a Buy at Jefferies - TipRanks
Why Is Cogent Biosciences Stock Surging Monday?Cogent Biosciences (NASDAQ:COGT) - Benzinga
Cogent Biosciences (NASDAQ:COGT) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Shares Gap UpHere's Why - MarketBeat
Cogent Biosciences, Inc. shares surged 7.2% in pre-market trading after the U.S. Food and Drug Administration (FDA) officially accepted its new drug application for a rare disease treatment and will initiate the review process. - Bitget
Cogent Biosciences shares are trading higher ... - Benzinga
Cogent Biosciences (COGT) FDA Update on Bezuclastinib for NonAdv - GuruFocus
Cogent Biosciences Says FDA Accepted Marketing Application for Bezuclastinib in Non-Advanced Systemic Mastocytosis - marketscreener.com
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - The Manila Times
Cogent Biosciences Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm) - TradingView
HighVista Strategies LLC Acquires 179,219 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. $COGT Shares Acquired by Fairmount Funds Management LLC - MarketBeat
Commodore Capital LP Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Boone Capital Management LLC Takes $13.57 Million Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires? - Insider Monkey
Cogent Biosciences Touts Bezuclastinib Pivotal Wins, Eyes Up to Three FDA Filings and U.S. Launches - MarketBeat
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned - AOL.com
(COGT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cogent Biosciences (COGT) Valuation Check After New SUMMIT Trial Results For Bezuclastinib - Sahm
Will Cogent Biosciences Inc benefit from AI trends2025 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
JPMorgan raises Cogent Biosciences (COGT) PT to $67 on sector model update - MSN
Cogent Biosciences (COGT) advances bezuclastinib-sunitinib combination with breakthrough therapy designation (BTD) - MSN
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):